SCHEMBL274462

SCHEMBL274462

CC(C)(C)OC(=O)N1C(=O)/C(=C\c2cccc(Cl)c2)c2ccc(Cl)cc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM4 O15151 1/20 0.43
TP53 P04637 1/20 0.43
MDM2 Q00987 1/20 0.43
PPARG P37231 1/20 0.41
APP P05067 1/20 0.39
MAPT P10636 1/20 0.39
SNCA P37840 1/20 0.39
KCNA3 P22001 1/20 0.38
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
BCHE P06276 1/20 0.36
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
STS P08842 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
ATM Q13315 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL277025 1.00 MDM4 (0.43) MDM4TP53MDM2PPARGAPP
SCHEMBL274463 1.00 MDM4 (0.43) MDM4TP53MDM2PPARGAPP
SCHEMBL699531 0.93 MAPT (0.43) MDM4TP53MDM2PPARGAPP
SCHEMBL279165 0.93 PPARG (0.45) MDM4TP53MDM2PPARGAPP
SCHEMBL275607 0.93 PPARG (0.45) MDM4TP53MDM2PPARGAPP
SCHEMBL275608 0.93 PPARG (0.45) MDM4TP53MDM2PPARGAPP
SCHEMBL275408 0.92 PPARG (0.50) MDM4TP53MDM2PPARGAPP
SCHEMBL13929141 0.92 MDM4 (0.41) MDM4TP53MDM2PPARGAPP
SCHEMBL279251 0.92 PPARG (0.50) MDM4TP53MDM2PPARGAPP
SCHEMBL4766463 0.92 MDM4 (0.41) MDM4TP53MDM2PPARGAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2398801-A1 3, 3' -SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-A1 SPIROINDOLINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-22 EP disclosed
WO-2010094622-A1 3, 3' -SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-7495007-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-02-24 US disclosed
US-20080009486-A1 SPIROINDOLINONE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT MDM4 3506/4885TP53 51/4885MDM2 918/4885
US-20080009486-A1 SPIROINDOLINONE DERIVATIVES RB1, PKD1, KRAS MDM4 1558/4885TP53 30/4885MDM2 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.